DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Corneal Neovascularization - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Corneal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Neovascularization and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Corneal Neovascularization Overview
- Therapeutics Development
- Pipeline Products for Corneal Neovascularization - Overview
- Pipeline Products for Corneal Neovascularization - Comparative Analysis
- Corneal Neovascularization - Therapeutics under Development by Companies
- Corneal Neovascularization - Therapeutics under Investigation by Universities/Institutes
- Corneal Neovascularization Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Corneal Neovascularization - Products under Development by Companies
- Corneal Neovascularization - Products under Investigation by Universities/Institutes
- Corneal Neovascularization - Companies Involved in Therapeutics Development
- Amakem NV
- Gene Signal International SA
- Sirnaomics, Inc.
For more information visit http://www.researchandmarkets.com/research/nbfpc3/corneal